Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 26, 2017

DrugPatentWatch Database Preview

EMEND Drug Profile

« Back to Dashboard

What is the patent landscape for Emend, and when can generic versions of Emend launch?

Emend is a drug marketed by Merck And Co Inc, Merck, and Msd Merck Co. and is included in three NDAs. There are three patents protecting this drug and four Paragraph IV challenges.

This drug has one hundred and twenty-one patent family members in forty-eight countries.

The generic ingredient in EMEND is aprepitant. There are twenty-one drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aprepitant profile page.

Summary for Tradename: EMEND

Patents:3
Applicants:3
NDAs:3
Suppliers / Packagers: see list3
Bulk Api Vendors: see list64
Clinical Trials: see list13
Patent Applications: see list58
Drug Prices:see details
DailyMed Link:EMEND at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Merck Co
EMEND
aprepitant
FOR SUSPENSION;ORAL207865-001Dec 17, 2015RXYesYes► Subscribe► Subscribe
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-002Mar 26, 2003ABRXYesYes► Subscribe► Subscribe
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-001Jan 25, 2008DISCNYesNo5,691,336► SubscribeYY ► Subscribe
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-003Jun 30, 2006ABRXYesNo8,258,132► SubscribeY ► Subscribe
Merck
EMEND
aprepitant
CAPSULE;ORAL021549-001Mar 26, 2003ABRXYesNo6,096,742► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot